STOCKS TELEGRAPH

Category: Mid Day Movers

  • Orchard Therapeutics (ORTX) Stock: What’s Happening Today?

    Orchard Therapeutics (ORTX) Stock: What’s Happening Today?

    Orchard Therapeutics plc (ORTX) is experiencing a remarkable surge in its market performance today, exhibiting a substantial gain of 97.77% and reaching a trading price of $15.98 at the latest trades.

    Additionally, the trading activity for Orchard Therapeutics stock has witnessed an atypical surge in volume, with over 6 million shares changing hands within the initial hour of the trading session. This notable surge contrasts sharply with the typical trading volume of 47.58K shares.

    The upswing in Orchard Therapeutics (ORTX) stock value coincides with the unveiling of an acquisition proposal. Kyowa Kirin, a leading Japanese pharmaceutical company, is set to acquire ORTX in a definitive agreement worth approximately $477.6 million.

    This acquisition aligns with Kyowa Kirin’s 2030 Vision, emphasizing innovative medical solutions and its commitment to life-changing medicines, particularly in rare diseases.

    Orchard Therapeutics’ gene therapy approach using genetically modified hematopoietic stem cells is at the forefront of genetic medicine, complementing Kyowa Kirin’s expertise. This strategic move will accelerate the development of ORTX’s MPS programs and other research initiatives.

    The combination of Orchard’s technology and Kyowa Kirin’s resources positions them to advance biopharmaceutical candidates across various therapeutic areas, including oncology and autoimmune diseases, with the potential to revolutionize medical care.

    In accordance with the established agreement, Kyowa Kirin is poised to orchestrate the acquisition of Orchard Therapeutics’ American Depositary Shares (ADSs) at a notable price of $16.00 per ADS in cash, amounting to approximately $387.4 million or ¥57.3 billion in value.

    This proposition represents a substantial premium of 144% over ORTX’s 30-day volume-weighted average ADS price leading up to October 4.

    As part of this transaction, Orchard Therapeutics (ORTX) shareholders will receive a non-transferable Contingent Value Right (CVR), entitling them to a cash payment of $1.00 per ADS, contingent on the approval of OTL-200 for Metachromatic Leukodystrophy (MLD) treatment in the United States, as explicitly outlined in the CVR Agreement.

  • ALX Oncology (ALXO) Stock Is Skyrocketing Today, Why?

    ALX Oncology Holdings Inc. (NASDAQ: ALXO) shares are experiencing a remarkable surge in the current market trading session, surging by an impressive 57.69% to reach a value of $7.58. Notably, the performance of ALX Oncology stock exhibited stability in the preceding session, registering a modest increase of 0.21% and concluding the session at $4.81.

    Nevertheless, it is noteworthy that ALXO stock has consistently demonstrated robust gains over the past month, accumulating a substantial rise of 116.81%. This noteworthy upswing in ALX Oncology’s stock value can be attributed to the release of interim findings from their cancer treatment research study.

    ALX Oncology (ALXO) has released promising interim Phase 2 results from its ASPEN-06 clinical trial, marking a significant advancement in the treatment of HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer. The trial evaluates the efficacy of evorpacept, an innovative CD47 blocking therapeutic developed by ALXO, in combination with trastuzumab, CYRAMZA, and paclitaxel.

    The study included 54 patients with second and third-line gastric/GEJ cancer, many of whom had previously received treatment with ENHERTU and checkpoint inhibitors. Evorpacept, administered at 30 mg/kg every two weeks, demonstrated a notable confirmed overall response rate (“ORR”) of 52% when combined with the other therapies. Importantly, the safety profile of evorpacept remained consistent with previous trials and was well-tolerated by patients.

    These interim findings compare favorably to the current standard of care, CYRAMZA + paclitaxel, for second-line gastric/GEJ cancer as established by the RAINBOW study. ALXO is encouraged by these results, marking the first presentation of positive randomized clinical trial data for any CD47 blocker. The company plans to release the final analysis of the ASPEN-06 study in the second quarter of 2024 and initiate Phase 3 in late 2024.

    This groundbreaking development highlights the potential of evorpacept as an immunotherapy agent for solid tumors, particularly in combination with anti-cancer antibodies. ALXO’s vision is to redefine the care continuum for advanced gastric cancer patients and revolutionize treatment options. Evorpacept’s unique attributes, such as inactive Fc effector function, make it a promising candidate in the realm of CD47 immune checkpoint pathway inhibition. ALX Oncology (ALXO)’s pioneering approach could lead to a therapeutic breakthrough in the field of gastric cancer treatment.

  • Why Is POINT Biopharma (PNT) Stock On The Rise Today?

    Why Is POINT Biopharma (PNT) Stock On The Rise Today?

    POINT Biopharma Global Inc. (NASDAQ: PNT) has experienced a notable surge of 85.04%, reaching $12.37 as of the latest observation during the current trading session.

    Moreover, POINT Biopharma’s equities have witnessed a significantly elevated trading activity, with over 24 million shares changing hands today, a substantial contrast to the usual daily average of 0.54 million shares.

    The ascent in PNT stock value can be attributed to the recent revelation of a takeover offer.

    POINT Biopharma (PNT) has entered a formal acquisition agreement with Eli Lilly and Company. This strategic move stems from Lilly’s interest in POINT Biopharma’s portfolio, specifically its advanced radioligand therapies, currently in clinical and preclinical phases.

    These therapies hold immense potential for precisely targeting cancer cells by coupling radioisotopes with specialized targeting molecules, thereby optimizing anti-tumor effectiveness while minimizing harm to healthy tissue.

    POINT is advancing pioneering radioligand therapies, such as PNT20021 for metastatic castration-resistant prostate cancer and PNT20031 for gastroenteropancreatic neuroendocrine tumors.

    Their late-stage clinical pipeline complements early-stage programs, and they operate advanced radiopharmaceutical facilities in Indianapolis and Toronto. These assets support their supply chain partnerships in securing radioisotopes and their precursors.

    In recent years, radiopharmaceuticals have shown significant promise in cancer treatment but remain in the early stages of their potential impact. Lilly’s acquisition of POINT marks the start of their investment in developing impactful radioligand medicines for challenging cancers, akin to their achievements in small-molecule and biologic oncology drug development.

    The transaction involves a cash tender offer by Lilly to acquire all outstanding POINT shares at $12.50 per share, totaling approximately $1.4 billion, with unanimous approval from both companies’ boards.

    This deal entails no financial contingencies and is anticipated to finalize by the conclusion of 2023, contingent upon customary closing prerequisites and regulatory authorizations.

    The acquisition cost signifies an 87% bonus above PNT’s concluding stock valuation on October 2, 2023, and a 68% surplus over the thirty-day mean cost. POINT Biopharma (PNT) board strongly recommends its shareholders participate in the tender offer.

  • SciSparc (SPRC) Stock: Why Is It On The Rise?

    SciSparc (SPRC) Stock: Why Is It On The Rise?

    The shares of SciSparc Ltd. (NASDAQ: SPRC) are currently experiencing a noteworthy surge in value, exhibiting an impressive upward movement of over 35%, with the stock currently trading at $5.00, according to the latest market data.

    Furthermore, there is a marked increase in trading activity for SciSparc stock, as evidenced by the trading volume exceeding 11 million shares at the time of composing this report, a substantial deviation from the typical average of 0.11 million shares.

    The catalyst behind this surge in SPRC stock can be attributed to the recent grant of a patent in Europe, which has significantly boosted its performance in the present market environment.

    SciSparc (SPRC) has just obtained a European patent titled “Combinations of Cannabinoids and N-Acylethanolamines” as part of their mission to improve the safety of cannabinoid treatments while maintaining their therapeutic benefits.

    This patent, in alignment with similar grants in the United States, Japan, and Australia, reinforces SciSparc’s pioneering role in cannabinoid technology innovation.

    The patent focuses on novel formulations and methods for enhancing the therapeutic effects of specific cannabinoids from the cannabis plant. It encompasses pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, offering versatile applications across various medical conditions amenable to cannabinoid-based treatments.

    SPRC’s asset portfolio continues to expand, encompassing intellectual property and revenue-generating assets. This emphasis on robust patent protection stems from SPRC’s profound belief in the vast therapeutic potential of cannabinoid-based medicines.

    Notably, SPRC has also initiated a pivotal clinical trial for SCI-210, a unique blend of cannabidiol (CBD) and SciSparc’s proprietary Palmitoylethanolamide (PEA), designed to address symptoms of Autism Spectrum Disorder (ASD). The trial, conducted in collaboration with Israel’s National Autism Research Center, exemplifies SPRC’s commitment to scientific rigor and patient safety. This randomized, double-blind, placebo-controlled study spanning 20 weeks involves 60 children aged 5-18, marking a significant stride in ASD research and treatment.

    The recent patent grant and pioneering clinical trial underscore SciSparc (SPRC) dedication to advancing cannabinoid-based therapies with a strong focus on safety and efficacy, positioning the company as a leader in this innovative field.

  • Takeover Bid Drives Vericity (VERY) Stock Up Today

    Takeover Bid Drives Vericity (VERY) Stock Up Today

    Vericity Inc. (NASDAQ: VERY) is experiencing a notable ascent in the current market. In the recent trading session, Vericity’s shares concluded at a price of $5.70, reflecting a remarkable monthly surge of nearly 100%. Furthermore, over the course of the past year, VERY stock has demonstrated substantial growth, achieving an impressive increase of more than 50%.

    In the early hours of today’s trading session, the value of VERY stock surged by a substantial 87.52%, reaching $11.12 at the latest assessment. This significant uptick in stock value is primarily attributable to an imminent takeover proposition.

    Vericity (VERY) has formally entered into a definitive merger agreement with iA American Holdings, Inc., a subsidiary of iA Financial Corporation, Inc. This merger is valued at approximately $170 million and is set to be an all-cash transaction. Vericity, primarily owned by J.C. Flowers & Co., a prominent private investment firm specializing in financial services, views this merger as a favorable proposition for its shareholders, highlighting the strength of its business operations.

    The merger with iA aims to accelerate Vericity’s strategic growth within the iA framework. It focuses on expanding the eFinancial platform, strengthening overall business operations, and creating new opportunities. J.C. Flowers has been a significant supporter of Vericity, aiding the company in adopting advanced technologies such as artificial intelligence and data analytics to reshape its business model.

    Under the merger agreement, each outstanding share of Vericity common stock, totaling 14,875,000 shares, will be converted into a cash payment of $11.43 per share, funded from iA’s existing cash reserves. This per-share offer represents an impressive 101% premium over Vericity’s closing stock price on October 2, 2023, just before the merger announcement, and the transaction has no financial conditions or contingencies.

    Vericity (VERY) board of directors unanimously supports the merger, aligning with the company’s strategic vision. The merger is expected to conclude in the first half of 2024, subject to customary closing conditions typical for such transactions. Overall, the merger between VERY and iA signifies a significant step forward in the financial services industry, driven by a commitment to innovation and growth.

  • Why Is SeaStar Medical (ICU) Stock Soaring?

    Why Is SeaStar Medical (ICU) Stock Soaring?

    The shares of SeaStar Medical Holding Corporation (NASDAQ: ICU) are experiencing a remarkable surge of 43.72% in the present market conditions, currently valued at $0.5993 per share.

    SeaStar’s stock performance has notably positioned it as one of the standout gainers of the week, boasting an impressive ascent of over 220% within the preceding five days.

    However, it’s essential to observe that the stock has suffered a significant devaluation of over 95% during the past year. This notable drop could offer an appealing opportunity for investors interested in adding this stock to their investment portfolios.

    In the current market landscape, ICU’s stock is on the ascent, spurred by a significant regulatory milestone. SeaStar Medical (ICU) recently earned the esteemed Breakthrough

    Device Designation from the U.S. Food and Drug Administration (FDA) for its revolutionary Selective Cytopheretic Device (SCD).

    Tailored for utilization in intensive care units (ICUs), the SCD caters to patients facing acute or chronic systolic heart failure and deteriorating renal function while anticipating a left ventricular assist device (LVAD) implantation.

    This FDA recognition is poised to expedite the SCD’s clinical advancement and regulatory evaluation, a noteworthy acknowledgment, as it’s only the ninth such distinction granted by the FDA’s Center for Biologics Evaluation and Research (CBER) since its establishment in 2015.

    Cardiorenal syndrome, typically occurring in severe heart failure cases, carries a grim prognosis. The SCD, however, has the potential to halt the deteriorating condition, especially the hyperinflammatory state driven by the immune system, offering a glimmer of hope.

    Supported by robust preclinical data and a pioneering human study conducted in collaboration with the University of Michigan, ICU asserts that the SCD represents a transformative approach to addressing hyperinflammation in critically ill chronic heart failure patients.

    Having secured FDA Breakthrough Device Designation for adult Acute Kidney Injury (AKI) previously and now for cardiorenal syndrome, ICU is positioned to expand its application to various medical conditions where hyperinflammation is a key factor.

    Further collaboration with the University of Michigan for a larger clinical study aims to bolster the case for a Premarket Approval (PMA) application to the FDA, cementing ICU’s position as a pioneer in innovative medical solutions.

  • EBET, Inc. Stock: Why the Stock Is Drowning Today

    EBET, Inc. Stock: Why the Stock Is Drowning Today

    Ebet Inc. is a technology services entity operating in the packaged software industry. Despite facing hurdles in terms of earnings growth, the company has demonstrated remarkable revenue growth. However, the recent trading activities surrounding EBET US stocks have been a mixture of surges and declines, causing a stir in the investment community.

    EBET, Inc. (EBET) is making headlines as its stock price stands at a mere $0.70, experiencing a noteworthy -15.15% plunge today. This dramatic shift in fortune has garnered attention, with a substantial trading volume of 367,910,000 shares adding to the intrigue.

    Recent Activities

    Amendment to Its Existing $30,000,000 Term Loan

    On October 2, 2023, EBET, Inc. (NASDAQ: EBET), a prominent global operator of online i-gaming casino websites, revealed a significant financial development.

    The company announced an amendment to its existing $30,000,000 Term Loan, which has resulted in an increase in borrowing availability. Additionally, EBET’s discretionary Revolving Loan has been upsized from $2,000,000 to $4,000,000.

    These changes have been facilitated through a Second Amendment to the Credit Agreement and a modification to the existing Forbearance Agreement with CPBF Lending, LLC, EBET’s lender. Collectively, these adjustments are encompassed within the “Amended Credit Agreements.”

    EBET’s latest Opening and Closing Stock Prices

    In yesterday’s trading, Ebet’s stock exhibited an opening price of $0.93 and a closing price of $0.95. The market capitalization stood at approximately $23.64 million, with the stock’s daily range fluctuating between a low of $0.67 and a high of $0.95.

    There was a total of 448.05 million shares in circulation, with a free float percentage of -3.31. The book value per share was reported at -0.55, and the trading volume for the day reached 7,803,710 shares.

    The 1-for-30 Reverse Stock Split

    On September 29, 2023, in an unexpected move, EBET announced a 1-for-30 reverse stock split on. The strategic decision aimed to consolidate the company’s stock, thereby increasing its individual value.

    The reverse stock split took effect at 4:01 pm (Eastern Time) on the same day, and the company’s common stock began trading on a post-split basis on October 2.

    This change led to a reduction in the number of outstanding shares of common stock, which previously stood at roughly 448.2 million shares.

  • Is The 15% Gain In Recruiter.com (RCRT) Stock Today Due To Anything Specific?

    Recruiter.com Group, Inc. (NASDAQ: RCRT) has witnessed a notable upswing of 15.50%, reaching $0.2340 during the initial trading hours as of the most recent update on Tuesday.

    In the preceding trading session, the valuation of Recruiter.com’s shares surged by 10.11%, culminating at $0.2026. This notable surge in RCRT stock value can be attributed to an ongoing takeover proposition.

    In a significant development, Recruiter.com (RCRT) has divulged that Futuris Company (OTC: FTRS), a distinguished authority in the realm of Human Capital Management (HCM), has formally agreed to acquire RCRT’s specialized healthcare staffing division, subject to the requisite approvals from clients.

    This strategic maneuver undertaken by Futuris firmly establishes its foothold within the domain of healthcare staffing, simultaneously reinforcing the shared commitment of both entities to broaden their service portfolios and facilitate expansive growth trajectories.

    The parameters of the agreement stipulate that specific client agreements currently held by Recruiter.com will be transitioned to Futuris or its affiliated entities. The compensation for this transaction encompasses a tranche of Futuris stock, appraised at $500,000, as well as a proportion of the ongoing gross profits, with an upper limit set at $2 million.

    Upon the consummation of the requisite closing conditions, including the essential green-lighting from clients, the transaction is poised for prompt finalization. Notably, the financial results for the second quarter terminating on June 30, 2023, have recently been released by Recruiter.com.

    Demonstrating its steadfast dedication to a streamlined and focused strategic trajectory, RCRT achieved noteworthy progress in the second quarter of 2023.

    By orchestrating a reduction in operational expenses by more than 60% from the preceding quarter and capitalizing on additional income derived from governmental credits, RCRT achieved a remarkable reduction of over 70% in its net loss and, additionally, attained a favorable adjusted EBITDA of $39.7 thousand.

    This quarter emerges as a pivotal juncture, substantiating RCRT’s resolute emphasis on technological advancements and solutions fueled by artificial intelligence.

    Harmonious with its overarching strategic blueprint, RCRT has recently embarked upon a groundbreaking endeavor: the announcement of a proposed asset acquisition concerning fintech assets from GoLogiq.

    Meticulously planned and executed over the preceding quarters, this strategic transaction has materialized in the formation of CognoGroup, Inc., a potential epicenter for RCRT’s current operational pursuits.

    Concurrently, RCRT has entered into a Securities Purchase Agreement to secure 1,000,000 Series A Preferred Stock of Atlantic Energy Solutions, an enterprise publicly quoted on the OTC Markets. These intricately calibrated initiatives eloquently reflect RCRT’s unwavering commitment to advancing its strategic mission.

  • What Explains 70% Gain In Novo Integrated (NVOS) Stock Today?

    Novo Integrated Sciences, Inc. (NASDAQ: NVOS) has demonstrated a remarkable ascent, with its shares surging by an impressive 70.80% to reach $0.1211 during the early trading session on Tuesday.

    This upward trajectory follows a recent setback, as Novo Integrated stock experienced a 10% decline, closing at $0.0710 in the previous trading session. The catalyst behind this robust movement is a consequential agreement unveiled today, which has elicited a pronounced positive response in the NVOS stock.

    In an announcement of paramount significance, Novo Integrated (NVOS) has divulged its collaboration in a joint venture endeavor with Farm 7 Group Inc., an esteemed Canadian corporation known as “F7.” This partnership is encapsulated within the joint venture agreement (“JV Agreement”), a meticulously structured document that delineates their cooperative journey.

    The crux of the JV Agreement lies in its commitment to the development, management, and orchestration of structured financial mechanisms that underpin the realization and inauguration of the Kenya Agricultural Cooperative Project. This undertaking, primarily centered in Kenya, is distinguished by its focus on agricultural pursuits.

    It is characterized by the completion of formalized contracts, spanning a substantial 9 million hectares, catering to food-based agricultural commodities. The potential yield from this venture is projected to scale up to an impressive $350 million in revenue.

    In accordance with the tenets of the JV Agreement, a 30-year initial term is established, with profit distribution set at 75% to F7 and 25% to Novo.

    Remarkably, F7 has procured binding commodity buyer contracts, and airtight commitments for the annual acquisition of up to 1.6 million metric tons of food-based harvested commodities such as cassava starch, yellow corn, wheat, soybean, and sunflower.

    This strategic maneuver foretells substantial financial reverberations for both collaborating entities. Within this nexus, Novo Integrated is entrusted with the integral responsibilities of administration and structured financial solutions, underscoring its pivotal role in the joint venture.

    In alignment with its steadfast commitment, NVOS is resolute in advancing the commercialization of its distinctive proprietary products. This commitment extends to enhancing its suite of indispensable services and solutions, which redefine the landscape of non-catastrophic healthcare delivery in both the present and the future.

    Concurrently, Novo Integrated has judiciously secured unsecured, non-dilutive financing through a 15-year debt instrument, amounting to $70,000,000 in principal. This financial infusion, accounting for approximately $55,000,000 in net proceeds after due consideration, assumes heightened significance within the prevailing financial landscape marked by stringent capital markets and elevated costs associated with capital procurement.

    The accrued financial strength is poised to be instrumental, providing Novo Integrated with the bedrock capital required to galvanize its three-pillar business model. This capital infusion augments the foundation for propelling further implementation and robust expansion, all while upholding the principles of the innovative Novo ethos.

  • What Has Been Driving The Near Intelligence (NIR) Stock Up Today?

    Near Intelligence, Inc. (NASDAQ: NIR) has exhibited an impressive surge of 3.30% during the premarket trading hours, currently standing at $0.58 as verified during the most recent assessment on Monday.

    This upward movement follows the previous trading session where Near Intelligence stock experienced a marginal decline of -1.15%, culminating at a closing value of $0.5654. This remarkable ascent has been accompanied by a notable development – a prominent global restaurant entity has turned to Near Intelligence for valuable operational insights.

    In a recent announcement, Near Intelligence (NIR) proudly declared its esteemed position as a reliable collaborator with eminent global quick-service restaurants (QSRs), actively in pursuit of refined data insights and comprehensive restaurant analytics.

    These QSR giants, collectively commanding an annual revenue stream approaching $90 billion, entrust the NIR Platform to guide their data-fueled business determinations. This strategic reliance on NIR fosters the augmentation of their business strategies, a pivotal adjustment in response to the fluid dynamics of dining preferences.

    The efficacy of NIR’s advanced analytical capacities empowers leading QSRs to deconstruct consumer movement and behavioral trajectories, brand associations, trade delineations, and evolving trends.

    The NIR platform equips decision-makers within the restaurant sphere with real-time data, thereby unveiling profound insights into consumer behavior, facilitating operational streamlining, and enabling the curation of bespoke patron experiences.

    This collective empowerment translates into a distinct competitive advantage, yielding augmented customer engagement, fortified operational efficiency, and a commendable escalation in revenue.

    Distinguished by its prestigious partnerships, NIR stands as the chosen confidante to numerous premier quick-service establishments across the globe. The platform’s proficiency in navigating vast reservoirs of high-fidelity data, while adhering to stringent privacy protocols, empowers QSRs to embrace a data-driven modus operandi.

    This fortified approach enhances operational agility, fosters well-informed decisions, and underpins the delivery of unparalleled patron encounters, ultimately cementing their dominance within the fiercely contested fast-food sector.

    A recent revelation from Near Intelligence (NIR) underscores its pivotal role in facilitating actionable insights for Earth.Vision, a valued customer engaged in real estate enterprises. The collaborative effort between NIR and Earth.Vision enabled the identification of customer demographics, meticulous analysis of trade geographies, and the astute assessment of cannibalization risks.

    This knowledge empowers prudent decisions, optimization of market strategies, and the successful culmination of real estate transactions.

    The versatile Near Platform played a pivotal role in this alliance, facilitating the creation of an impressive array of 3,500 comprehensive location reports. These reports comprehensively illuminated customer profiles, prevailing establishment locales, and the potential for expansion into nascent markets.

    The distinct competitive advantage harnessed through this collaboration is mirrored in Earth.Vision’s enduring associations with a diverse clientele. This is eloquently reflected through a total of 488 successfully sealed deals, executed in tandem with NIR.

    Anticipating further developments, NIR is poised to unveil its financial results for the second quarter concluded on June 30, 2023. This announcement is scheduled for release subsequent to the cessation of trading today, offering stakeholders and industry observers a glimpse into NIR’s financial health and its ongoing trajectory.